Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dr. Richard Maziarz and Dr. Roisin O'Cearbhaill Named Co-Principal Investigators for Galinpepimut-S (GPS) – Pembrolizumab Phase 1/2 Basket Trial Immune Response Data from the Phase 2b Nelipepimut-S...
-
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
-
Aligned with FDA on Phase 3 Registration-Enabling Trial for Galinpepimut-S (GPS) in Acute Myeloid Leukemia; Trial Expected to Start in Q2 2019 Enrollment of Phase 1/2 Basket Trial of GPS plus...
-
Clinically Meaningful and Statistically Significant Decrease in the Frequency of Clinically Detected Recurrences in the TNBC Cohort Treated with Nelipepimut-S plus Trastuzumab (p=0.004) Specific...
-
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
-
Agreement on new open-label randomized registrational Phase 3 study in patients in second complete remission (CR2) poised to reduce sample size, time to primary endpoint and costs Fast-Track and...
-
Data Expected in Fourth Quarter of 2019 Second Clinical Study of Nelipepimut-S Plus Trastuzumab After Recently Announced Positive Phase 2b Study in Low-expression HER2 or Triple Negative Breast...
-
Conference call today at 8:00 a.m. ET NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical...
-
Final data from Phase 2b clinical trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) were previously presented at the European Society for Medical Oncology (ESMO) 2018...
-
Follows Dismissal by Court of All Claims Against SELLASDebenture and All Security Interests Held by JGB Terminated NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc....